![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University of Kansas Almond Board of California |
---|---|
Information provided by: | University of Kansas |
ClinicalTrials.gov Identifier: | NCT00603876 |
The purpose of the study is to evaluate the effects of 100-110 grams of almonds (about ¾ cupful) daily on the lipoprotein profile when given to patients on a statin drug. The study will compare the effects on the lipoprotein profile to patients who eat almonds and those patients not eating almonds.
Condition | Intervention | Phase |
---|---|---|
Hyperlipidemia |
Dietary Supplement: Almonds |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Efficacy of Almonds Added to Chronic Statin Therapy |
Estimated Enrollment: | 50 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
2: Experimental
Step 1 dietary counseling plus 100-110 grams of almonds daily
|
Dietary Supplement: Almonds
100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
|
1: No Intervention
Step 1 dietary counseling
|
The primary objectives of this study are to determine the changes in the lipid profile [LDL-C, HDL-C, triglycerides, total cholesterol], LDL-C particle size, and the emerging risk factor Lp(a) when 100-110 g of almonds daily are added to statin therapy. Also, all subjects will receive Step I dietary counseling.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Janelle Ruisinger, Pharm.D. | (913) 588-2608 | jruisinger@kumc.edu |
United States, Kansas | |
University of Kansas Medical Center | Recruiting |
Kansas City, Kansas, United States, 66160 | |
Contact: Janelle Ruisinger, Pharm.D. 913-588-2608 jruisinger@kumc.edu | |
Principal Investigator: Janelle Ruisinger, Pharm.D. | |
KU MedWest | Recruiting |
Shawnee, Kansas, United States, 66217 | |
Contact: Janelle Ruisinger, Pharm.D. 913-588-8526 jruisinger@kumc.edu | |
Principal Investigator: Janelle Ruisinger, Pharm.D. |
Principal Investigator: | Janelle Ruisinger, Pharm.D. | University of Kansas |
Responsible Party: | University of Kansas Medical Center ( Janelle Ruisinger, Pharm.D. ) |
Study ID Numbers: | KU FY08 GRF, 10998 |
Study First Received: | January 16, 2008 |
Last Updated: | November 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00603876 |
Health Authority: | United States: Institutional Review Board |
Metabolic Diseases Hyperlipidemias Metabolic disorder Dyslipidemias Lipid Metabolism Disorders |